Granger-Geweke causality (GGC) is a powerful and popular method for identifying directed functional ('causal') connectivity in neuroscience. In a recent paper, Stokes and Purdon (2017b) raise several concerns about its use. They make two primary claims: (1) that GGC estimates may be severely biased or of high variance, and (2) that GGC fails to reveal the full structural/causal mechanisms of a system. However, these claims rest, respectively, on an incomplete evaluation of the literature, and a misconception about what GGC can be said to measure. Here we explain how existing approaches resolve the first issue, and discuss the frequently-misunderstood distinction between functional and effective neural connectivity which underlies Stokes and Purdon's second claim.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neuroimage.2018.05.067 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force.
Bipolar Disord
May 2024
Psychiatry Research Unit, University of Fribourg, Fribourg, Switzerland.
Background: Abnormalities in dopamine and norepinephrine signaling are implicated in cognitive impairments in bipolar disorder (BD) and attention-deficit hyperactivity disorder (ADHD). This systematic review by the ISBD Targeting Cognition Task Force therefore aimed to investigate the possible benefits on cognition and/or ADHD symptoms and safety of established and off-label ADHD therapies in BD.
Methods: We included studies of ADHD medications in BD patients, which involved cognitive and/or safety measures.
Can magnetic resonance imaging enhance the assessment of potential new treatments for cognitive impairment in mood disorders? A systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task Force.
Bipolar Disord
September 2022
Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Background: Developing treatments for cognitive impairment is key to improving the functioning of people with mood disorders. Neuroimaging may assist in identifying brain-based efficacy markers. This systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task Force examines the evidence from neuroimaging studies of pro-cognitive interventions.
View Article and Find Full Text PDFRandomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force.
Bipolar Disord
June 2022
Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.
Background: Cognitive impairments are an emerging treatment target in mood disorders, but currently there are no evidence-based pro-cognitive treatments indicated for patients in remission. With this systematic review of randomised controlled trials (RCTs), the International Society for Bipolar Disorders (ISBD) Targeting Cognition Task force provides an update of the most promising treatments and methodological recommendations.
Methods: The review included RCTs of candidate pro-cognitive interventions in fully or partially remitted patients with major depressive disorder or bipolar disorder.
Reply to Barnett et al.: Regarding interpretation of Granger causality analyses.
Proc Natl Acad Sci U S A
July 2018
Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA 02114;
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!